Selected article for: "early initiation and highly potent therapy"
Author: Ashish Goyal; E. Fabian Cardozo-Ojeda; Joshua T Schiffer
Title: Potency and timing of antiviral therapy as determinants of duration of SARS CoV-2 shedding and intensity of inflammatory response
  • Document date: 2020_4_14
    • ID: d7stppv5_25
    Snippet: Both high drug potency and extremely early treatment initiation during the presymptomatic stage of infection were required to significantly lower viral area under the curve. Even highly potent therapy during the earliest symptomatic phase at days 4-5 had only a slight impact on viral area under the curve, reflecting the fact that most virus and infected cells are generated during the first 2-3 days of SARS CoV-2 infection (Fig. 5b) ......
    Document: Both high drug potency and extremely early treatment initiation during the presymptomatic stage of infection were required to significantly lower viral area under the curve. Even highly potent therapy during the earliest symptomatic phase at days 4-5 had only a slight impact on viral area under the curve, reflecting the fact that most virus and infected cells are generated during the first 2-3 days of SARS CoV-2 infection (Fig. 5b) .

    Search related documents:
    Co phrase search for related documents
    • curve viral area and high drug potency: 1
    • curve viral area and SARS infection: 1, 2, 3, 4, 5
    • curve viral area and symptomatic phase: 1, 2, 3
    • curve viral area and treatment initiation: 1, 2, 3, 4, 5, 6
    • curve viral area and viral area: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • high drug and infected cell: 1, 2, 3
    • high drug and infected cell virus: 1, 2
    • high drug and SARS infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • high drug and significantly lower: 1, 2, 3
    • high drug and viral area: 1
    • high drug potency and SARS infection: 1
    • high drug potency and viral area: 1
    • highly potent therapy and symptomatic phase: 1
    • infected cell and SARS infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • infected cell and significantly lower: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • infected cell and symptomatic phase: 1
    • infected cell and treatment initiation: 1
    • infected cell virus and SARS infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
    • infected cell virus and significantly lower: 1